Immutep
Immutep Logo
About Immutep
Immutep Ltd is a biotechnology company specializing in the development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha (IMP321), is in clinical development for various cancers. The company’s pipeline includes multiple clinical-stage and preclinical candidates targeting indications such as non-small cell lung cancer, head and neck squamous cell carcinoma, metastatic breast cancer, soft tissue sarcoma, and autoimmune diseases. Immutep collaborates with global pharmaceutical partners and is recognized for its expertise in LAG-3 biology.
Address
Australia Square, Level 32 264 George Street
Sydney, 2000
Australia
Year founded
2000
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
